Hypusine

a new target for therapeutic intervention in diabetic inflammation.

Bernhard Maier, Sarah A. Tersey, Raghu Mirmira

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Diabetes, a disorder of glucose homeostasis, has risen to near epidemic proportions world-wide and may be the single most important risk factor for cardiovascular, kidney, and eye disease. Dysfunction and destruction of islet beta cells, caused in part by the systemic or local release of pro-inflammatory cytokines, underlies all forms of diabetes. A major effort in diabetes research in recent years has been to identify new factors or pathways that can be therapeutically targeted to reduce cytokine action on the beta cell. Recent studies have suggested that an ancient and poorly understood protein, eIF5A, may be critical to cytokine release and signaling. Interestingly, eIF5A is the only protein to contain the unique amino acid hypusine, which is a polyamine-derived modification of amino acid lysine residue. This modification is catalyzed by the sequential actions of the inhibitable enzymes deoxyhypusine synthase and deoxyhypusine hydroxylase. Because the hypusine modification is absolutely required for eIF5A action in cytokine signaling, we propose that this modification could serve as a new drug target for islet beta cell protection in the setting of diabetic inflammation.

Original languageEnglish
Pages (from-to)18-23
Number of pages6
JournalDiscovery medicine
Volume10
Issue number50
StatePublished - Jul 2010

Fingerprint

Cytokines
Inflammation
deoxyhypusine hydroxylase
Islets of Langerhans
Amino Acids
Cytoprotection
Eye Diseases
Polyamines
Kidney Diseases
Therapeutics
Lysine
Homeostasis
Cardiovascular Diseases
Glucose
hypusine
Enzymes
Research
Pharmaceutical Preparations
Proteins
eukaryotic translation initiation factor 5A

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hypusine : a new target for therapeutic intervention in diabetic inflammation. / Maier, Bernhard; Tersey, Sarah A.; Mirmira, Raghu.

In: Discovery medicine, Vol. 10, No. 50, 07.2010, p. 18-23.

Research output: Contribution to journalArticle

@article{2512c76d02b24d3c9b4d46dc51f0df0d,
title = "Hypusine: a new target for therapeutic intervention in diabetic inflammation.",
abstract = "Diabetes, a disorder of glucose homeostasis, has risen to near epidemic proportions world-wide and may be the single most important risk factor for cardiovascular, kidney, and eye disease. Dysfunction and destruction of islet beta cells, caused in part by the systemic or local release of pro-inflammatory cytokines, underlies all forms of diabetes. A major effort in diabetes research in recent years has been to identify new factors or pathways that can be therapeutically targeted to reduce cytokine action on the beta cell. Recent studies have suggested that an ancient and poorly understood protein, eIF5A, may be critical to cytokine release and signaling. Interestingly, eIF5A is the only protein to contain the unique amino acid hypusine, which is a polyamine-derived modification of amino acid lysine residue. This modification is catalyzed by the sequential actions of the inhibitable enzymes deoxyhypusine synthase and deoxyhypusine hydroxylase. Because the hypusine modification is absolutely required for eIF5A action in cytokine signaling, we propose that this modification could serve as a new drug target for islet beta cell protection in the setting of diabetic inflammation.",
author = "Bernhard Maier and Tersey, {Sarah A.} and Raghu Mirmira",
year = "2010",
month = "7",
language = "English",
volume = "10",
pages = "18--23",
journal = "Discovery medicine",
issn = "1539-6509",
publisher = "Discovery Medicine",
number = "50",

}

TY - JOUR

T1 - Hypusine

T2 - a new target for therapeutic intervention in diabetic inflammation.

AU - Maier, Bernhard

AU - Tersey, Sarah A.

AU - Mirmira, Raghu

PY - 2010/7

Y1 - 2010/7

N2 - Diabetes, a disorder of glucose homeostasis, has risen to near epidemic proportions world-wide and may be the single most important risk factor for cardiovascular, kidney, and eye disease. Dysfunction and destruction of islet beta cells, caused in part by the systemic or local release of pro-inflammatory cytokines, underlies all forms of diabetes. A major effort in diabetes research in recent years has been to identify new factors or pathways that can be therapeutically targeted to reduce cytokine action on the beta cell. Recent studies have suggested that an ancient and poorly understood protein, eIF5A, may be critical to cytokine release and signaling. Interestingly, eIF5A is the only protein to contain the unique amino acid hypusine, which is a polyamine-derived modification of amino acid lysine residue. This modification is catalyzed by the sequential actions of the inhibitable enzymes deoxyhypusine synthase and deoxyhypusine hydroxylase. Because the hypusine modification is absolutely required for eIF5A action in cytokine signaling, we propose that this modification could serve as a new drug target for islet beta cell protection in the setting of diabetic inflammation.

AB - Diabetes, a disorder of glucose homeostasis, has risen to near epidemic proportions world-wide and may be the single most important risk factor for cardiovascular, kidney, and eye disease. Dysfunction and destruction of islet beta cells, caused in part by the systemic or local release of pro-inflammatory cytokines, underlies all forms of diabetes. A major effort in diabetes research in recent years has been to identify new factors or pathways that can be therapeutically targeted to reduce cytokine action on the beta cell. Recent studies have suggested that an ancient and poorly understood protein, eIF5A, may be critical to cytokine release and signaling. Interestingly, eIF5A is the only protein to contain the unique amino acid hypusine, which is a polyamine-derived modification of amino acid lysine residue. This modification is catalyzed by the sequential actions of the inhibitable enzymes deoxyhypusine synthase and deoxyhypusine hydroxylase. Because the hypusine modification is absolutely required for eIF5A action in cytokine signaling, we propose that this modification could serve as a new drug target for islet beta cell protection in the setting of diabetic inflammation.

UR - http://www.scopus.com/inward/record.url?scp=79959769631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959769631&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 18

EP - 23

JO - Discovery medicine

JF - Discovery medicine

SN - 1539-6509

IS - 50

ER -